A pattern forming method includes forming a pattern film on a substrate. The pattern film includes a triptycene derivative having a triptycene skeleton. The triptycene skeleton includes a first plane in which position 1, position 8, and position 13 of the triptycene skeleton are arranged, and a second plane in which position 4, position 5, and position 16 of the triptycene skeleton are arranged. The triptycene derivative includes a first side chain on a one plane side, the one plane side being on a side of one plane from among the first plane and the second plane, and a second side chain on another plane side or on the one plane side, the another plane side being on a side of another plane from among the first plane and the second plane. The second side chain is different from the first side chain in an etching selectivity ratio.

Method for separating the diamondoids by liquid chromatography from a sample of iso-alkanes and cycloalkanes, or from a mixture of organic compounds, this method comprising introducing the sample into a column comprising a stationary phase comprising a material capable of forming inclusion complexes with the diamondoids, eluting with an eluent, and collecting the eluted fraction.

The present invention is directed to compositions and methods using triptycene derivatives (TCDs) for three way junctions (TWJs).

The present disclosure concerns synthesis and anion binding features of poly-cyanostilbene macrocycles of Formula (I): ##STR00001##

There are described ROR modulators of the formula (I),

##STR00001##

or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR activity, for example, autoimmune and/or inflammatory disorders.

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group XY is NHSO.sub.2; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or polycyclic heterocycloalkyl group, each of which is optionally substituted by one or more groups selected from haloalkyl, alkyl, alkenyl, alkynyl and (CR.sub.16R.sub.17).sub.mR.sub.18, where m is 0 to 6; L is a direct bond or a group (CR.sub.14R.sub.15).sub.n, where n is 1 or 2; R.sub.1 is H, CN, Cl or F or alkyl; R.sub.2 is selected from COOH and a tetrazolyl group; R.sub.3 is selected from H, halo, alkoxy and alkyl; R.sub.4 is selected from H and halo; R.sub.5 is selected from H, alkyl, haloalkyl, SO.sub.2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R.sub.6 is H; R.sub.7 is selected from H, CN, haloalkyl, halo, SO.sub.2-alkyl, SO.sub.2NR.sub.12R.sub.13, heteroaryl, CONR.sub.10R.sub.11 and alkyl, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R.sub.9 is selected from H, alkyl and halo; Rio, R.sub.1, R.sub.12 and R.sub.13 are each independently H or alkyl; R.sub.14 and R.sub.15 are each independently H, halo or alkyl; R.sub.16 and R.sub.17 are each independently H, halo, haloalkyl or alkyl; and each R.sub.18 is independently selected from OH, CN, alkoxy and halo. Further aspects of the invention relate to such compounds for use in the field of immune-oncology and related applications.

##STR00001##

Giant p-(R)calixarenes, a process for the preparation of giant p-(R)calixarenes with high yields, and their use as the constitution of a material or in the context of the reinforcement of the material.

Disclosed herein are embodiments of methods for preparing aminated or alkylaminated CNTs wherein the aminated or alkylaminated CNTs are obtained in a reaction by reacting the CNTs with an aminating or alkylaminating reagent in a non-hazardous solvent or a non-hazardous solvent-deionized water mixture. The CNTs may be single-walled, double-walled or multi-walled CNTs. The disclosed processes for amination and alkylamination do not require treatment with concentrated acid, and with the use of solvent, the CNTs and aminating compound or alkylaminating compound are mixed thoroughly throughout the reaction.

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

The invention relates to compounds according to formula (1), said compounds being suitable for use in electronic devices, in particular in organic electroluminescent devices.